Overview

A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

This is a first-in-human, open-label, multicenter, dose-escalation and expansion study designed to investigate SBT6290 administered alone and in combination with pembrolizumab in advanced solid tumors associated with Nectin-4 expression.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Silverback Therapeutics

Treatments:

Pembrolizumab